Elicio Therapeutics is a clinical-stage biotechnology company focused on developing innovative cancer immunotherapies. The company leverages the natural power of the lymph nodes to enhance the immune system's response against tumors. Elicio's targeted delivery approach aims to generate robust immune responses by activating and amplifying cancer-fighting T cells, potentially enabling patients to combat aggressive cancers more effectively. The company operates in the immuno-oncology market, serving patients battling various forms of cancer. Elicio's business model revolves around the research, development, and clinical trials of its proprietary therapies, with revenue generated through partnerships, grants, and future commercialization of successful treatments. The company's mission is to revolutionize cancer treatment by providing patients with the best possible outcomes through cutting-edge immunotherapy solutions.

Keywords: immunotherapy, lymph nodes, cancer treatment, T cells, biotechnology, clinical-stage, oncology, immune response, tumor targeting, cancer immunotherapies.